AzTrials
AzTrials

Psoriatic Arthritis (PsA)PPIDCNCT07772544

Prevention of Psoriatic Arthritis Inflammation Through Digital Care: A Feasibility Mixed-Methods Study

A study testing iPROLEPSIS Digital Health Ecossystem in people with Psoriatic Arthritis (PsA), run by Sociedade Portuguesa de Reumatologia at 4 sites in 2 countries.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record

Search all trials

Trial summary

This is an international, multicentre, feasibility mixed-methods, single-arm study evaluating the implementation of the iPROLEPSIS digital health promotion programme for adults with psoriatic arthritis (PsA) in real-world clinical practice. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Psoriatic Arthritis (PsA)
What is being tested?
iPROLEPSIS Digital Health Ecossystem
Could I receive a placebo?
No, everyone receives an active treatment
How many people
72 participants
Where
4 sitesin 2 countries
Study dates
Sep 2026to Dec 2027
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Willing and able to provide informed consent
  • Female or male, aged 18 years or older at the time of enrolment
  • Diagnosed with psoriatic arthritis
  • Had a rheumatology appointment in the past 12 months
  • Owns a smartphone (Android) compatible with the study apps
  • Willing to use the study smartwatch (Garmin Vivoactive 5) for the 12-month follow-up period
Show all 9Show fewer
  • Proficient in the local language
  • Willing and able to provide informed consent
  • Involved in the clinical follow-up of PsA patients enrolled in the study

Who cannot join

  • Illiteracy or inability to comply with the study protocol (e.g., due to hearing or visual impairments or significant cognitive impairment)
  • Lack of access to the necessary technology to participate in the study (e.g., smartphone or stable internet connection)

Trial locations and contacts

4 sites in 2 countries. Contact the study team or a site near you to ask about taking part.

Ana Maria Rodrigues, MD, PhD contact

+351 965555061

ana.m.rodrigues@nms.ul.pt

Cátia Gonçalves, PhD contact

catia.goncalves@nms.unl.pt

4 sites in 2 countries

Portugal3 sites
  • Unidade Local de Saúde de Aveiro, Serviço de Reumatologia, Hospital Infante Dom Pedro

    Aveiro

    Anabela Barcelos, MD, PhD, +351 966894176, barcelos.anabela@gmail.com

  • Unidade Local de Saúde de São José, Serviço de Reumatologia, Hospital Santo António dos Capuchos

    Lisbon

    Ana Teresa Melo, MD, +351 918613549, anateresamelo1992@gmail.com

  • Unidade Local de Saúde de São João, Serviço de Reumatologia, Hospital São João

    Porto

    Alexandra Bernardo, MD, +351 938507343, alexbernardo@sapo.pt

Other trials in Portugal

Greece1 site
  • Hipokrateion Hospital Thessaloniki

    Thessaloniki

    Ioanna Katsigianni, MD, +30 231 089 2000, katsigianniioan@gmail.com

Other trials in Greece

About this study

Official title: iPROLEPSIS-PPIDC: Prevention of Psoriatic Arthritis Inflammation Through Digital Care: A Feasibility Mixed-Methods Study

This is an international, multicentre, feasibility mixed-methods, single-arm study evaluating the implementation of the iPROLEPSIS digital health promotion programme for adults with psoriatic arthritis (PsA) in real-world clinical practice.

The study will enrol 72 adults with PsA (18 participants per country) across Portugal, the Netherlands, Greece, and the United Kingdom. Participants will be followed for 12 months, including a 1-month baseline monitoring period without intervention, followed by an 11-month intervention period during which participants will use the iPROLEPSIS digital health ecosystem. The iPROLEPSIS ecosystem integrates multiple digital health tools designed to support lifestyle management, self-monitoring, and patient engagement in PsA care. Participants will use the miPROLEPSIS app for active and passive data collection and personalised lifestyle recommendations related to diet and physical activity; biAURA for sleep and stress management using binaural beats; iPROLEPSIS Games to promote physical and emotional well-beingthrough serious games; and the miPROLEPSIS Joint Landmarker app for video-based functional assessments. The ecosystem will also integrate data from a Garmin vívoactive 5 smartwatch and wireless earbuds. Healthcare professionals involved in participant follow-up will access a dedicated clinical dashboard to support monitoring and clinical management. The primary objective of this feasibility study is to evaluate the usability of the iPROLEPSIS digital health ecosystem among patients with PsA and healthcare professionals using the System Usability Scale (SUS) and the eHealth UsaBility Benchmarking Instrument (HUBBI). Secondary objectives include assessing participant retention, acceptability of study participation, engagement with the digital health tools, adherence to study procedures, and identifying barriers and facilitators influencing the implementation of the digital health programme in routine clinical practice.The study will also generate preliminary evidence regarding potential changes in clinical and patient-reported outcomes associated with the use of the iPROLEPSIS ecosystem and include a preliminary budget impact analysis to inform the design of a future larger-scale clinical trial.

Being tested
iPROLEPSIS Digital Health Ecossystem
Keywords
Psoriatic Arthritis, Digital Health, Feasibility Study, Usability, Disease Self-Management, Digital Biomarkers, Remote Monitoring, eHealth
Medical subject headings
Arthritis, Psoriatic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • iPROLEPSIS Digital Health EcossystemBehavioural

    The iPROLEPSIS Digital Health Programme is a multimodal digital health intervention designed to support self-management, healthy lifestyle behaviours, and remote clinical follow-up in adults with psoriatic arthritis. Participants will use the miPROLEPSIS mobile application for symptom monitoring, passive and active data collection, and personalised lifestyle recommendations; biAURA for sleep and stress management; iPROLEPSIS Games to promote physical and emotional well-being; and the miPROLEPSIS Joint Landmarker application for video-based functional assessment. The ecossystem also integrates a smartwatch and wireless earbuds.

    Healthcare professionals will use a dedicated clinical dashboard to monitor participant data and support clinical management throughout the intervention period.

Study groups in NCT07772544
Study groupRoleWhat they receive
iPROLEPSIS Digital Health EcossystemExperimentalParticipants with psoriatic arthritis will undergo a 12-month study period consisting of a 1-month baseline monitoring phase followed by an 11-month intervention phase. During the intervention period, participants will receive the iPROLEPSIS digital health programme , integrated with a wearable smartwatch and wireless earbuds. Healthcare professionals involved in participant follow up will use a dedicated clinical dashboard.
Receives: Behavioral: iPROLEPSIS Digital Health Ecossystem

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. System Usability Scale (SUS)

    A validated 10-item questionnaire assessing ease of system use, scored on a 5-point Likert scale and converted to a 0-100 scale. A score ≥68 indicates above-average usability.

    Measured: T0 (Month 1), T3 (Month 4), and T11 (Month 12); Healthcare professionals: T11 (Month 12)

  2. eHealth UsaBility Benchmarking instrument (HUBBI)

    A structured heuristic tool assessing usability across seven domains (Basic System Performance, Task-Technology Fit, Interface Design, Navigation \& Structure, Information \& Terminology, Guidance \& Support, Satisfaction). Results are presented as categorical ratings (Good, Moderate, Insufficient, Poor).

    Measured: T0 (Month 1), T3 (Month 4), and T11 (Month 12); Healthcare professionals: T11 (Month 12)

Secondary outcomes (42)
  1. Acceptability

    Number of eligible participants who agree to participate in the study.

    Measured: Baseline

  2. Perceptions of acceptability, barriers, facilitators, and experiences (patients)

    Semi-structured focus group interviews

    Measured: T11 (Month 12)

  3. Step counts

    Count of steps collected unobtrusively from the smartwatch of patient to measure physical activity. Patients will wear the smartwatch daily

    Measured: Continuous, throughout 12 months

  4. Accelerometer data

    Accelerometer data collected unobtrusively from smartphone of patient and smartwatch to measure physical activity. Patients will wear the smartwatch daily

    Measured: Continuous, throughout 12 months

  5. Number of Flares Reported via the miPROLEPSIS Application

    Number of disease flares self-reported by patients directly through the miPROLEPSIS application.

    Measured: Continuous throughout 12 months

  6. Number of Flares Reported via Patient and Rheumatologist

    Count of disease flares reported using the structured Patient and Rheumatologist flare questionnaires developed in the iPROLEPSIS-PDPID study, completed during clinical visits.

    Measured: Baseline, T0 (Month 1), T3 (Month 4), and T11 (Month 12);

  7. Body Mass Index (BMI)

    Calculated as weight in kilograms divided by the square of height in meters (kg/m²). Used to classify nutritional status (underweight, normal weight, overweight, obesity).

    Measured: Baseline

  8. Minimal Disease Activity (MDA) status

    Minimal Disease Activity status based on predefined criteria, determined from joint counts, pain, global activity, and function.

    Measured: Baseline, T0 (Month 1), T3 (Month 4), and T11 (Month 12)

  9. Psoriatic Arthritis Disease Activity Score (PASDAS)

    Composite disease activity score combining clinical and patient-reported variables. Total score ranges from 0 to 10; higher scores indicate more active disease. Low disease activity is defined as a score <3.2.

    Measured: Baseline, T0 (Month 1), T3 (Month 4), and T11 (Month 12)

  10. Disease Activity in Psoriatic Arthritis (DAPSA) Score

    Composite score derived from tender joint count (0-68), swollen joint count (0-66), C-reactive protein level (mg/dL), patient pain (0-10 cm VAS), and patient global assessment (0-10). Higher scores indicate more active disease.

    Measured: Baseline, T0 (Month 1), T3 (Month 4), and T11 (Month 12)

  11. Psoriatic Arthritis Impact of Disease (PsAID)

    Validated patient-reported measure assessing disease impact across domains such as pain, fatigue, work, and emotional well-being

    Measured: Baseline, T0 (Month 1), T3 (Month 4), and T11 (Month 12)

  12. Arthritis Self-Efficacy Scale (ASES)

    8-item scale measuring perceived self-efficacy in managing pain and other arthritis-related symptoms. Scores range from 10 to 100, with higher scores indicating greater self-efficacy.

    Measured: Baseline, T0 (Month 1), T3 (Month 4), and T11 (Month 12)

  13. Patient Health Questionnaire-9 (PHQ-9)

    9-item instrument for screening and measuring the severity of depressive symptoms in the previous two weeks. Score ranges from 0 to 27. Higher scores indicate more severe depressive symptoms

    Measured: Baseline, T0 (Month 1), T3 (Month 4), and T11 (Month 12)

  14. Perceived Stress Scale (PSS)

    Self-reported questionnaire measuring the degree to which individuals perceive their life situations as stressful, over the past month. Scores are calculated by summing item responses, with higher scores indicating greater perceived stress.

    Measured: Baseline, T0 (Month 1), T3 (Month 4), and T11 (Month 12)

  15. Short Form-36 Health Survey (SF-36)

    Standardised questionnaire assessing assessing health-related quality of live across eight domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Scores are transformed to a 0-100 scale. Higher scores indicate better health status.

    Measured: Baseline, T0 (Month 1), T3 (Month 4), and T11 (Month 12)

  16. International Physical Activity Questionnaire - Short Form (IPAQ-SF)

    Self-reported physical activity levels across intensity domains (walking, moderate, vigorous), duration, and frequency over the past 7 days

    Measured: T0 (Month 1), T3 (Month 4), and T11 (Month 12)

  17. Health Assessment Questionnaire Disability Index (HAQ-DI)

    20-item scale assessing difficulties in performing daily activities. Responses range from 0 (no difficulty) to 3 (unable to do). Higher scores indicate worse functional disability.

    Measured: Baseline, T0 (Month 1), T3 (Month 4), and T11 (Month 12)

  18. 14-item Mediterranean Diet Adherence Screener (14-MEDAS)

    Questionnaire assessing adherence to Mediterranean dietary pattern. Score ranges from 0 to 14; higher scores reflect greater adherence.

    Measured: Baseline, T0 (Month 1), T3 (Month 4), and T11 (Month 12)

  19. EuroQoL 5-Dimensions 5-Levels (EQ-5D-5L)

    Standardised instrument measuring quality of life across five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Includes an index score and visual analogue scale (VAS).

    Measured: Baseline, T0 (Month 1), T3 (Month 4), and T11 (Month 12)

  20. Work Productivity and Activity Impairment (WPAI)

    Self-reported questionnaire measuring the degree to which health problems affect work productivity and regular activities. Includes absenteeism, presenteeism, and overall work and activity impairment.

    Measured: Baseline, T0 (Month 1), T3 (Month 4), and T11 (Month 12);

  21. Healthcare utilisation

    Self-reported use of healthcare services, including visits to GPs and specialists.

    Measured: Baseline, T0 (Month 1), T3 (Month 4), and T11 (Month 12)

  22. Safety assessment

    Number of adverse events (AEs) and serious adverse events (SAEs).

    Measured: Baseline, T0 (Month 1), T3 (Month 4), and T11 (Month 12)

  23. Heart rate

    Heart rate collected unobtrusively from smartwatch of patient. Patients will wear the smartwatch daily

    Measured: Continuous throughout 12 months

  24. Heart rate variability

    Heart rate variability (HRV) collected unobtrusively from the patient's smartwatch to assess variations in heart rate. This is a feature provided by the smartwatch. Patients will wear the smartwatch daily.

    Measured: Continuous throughout 12 months

  25. Stress (digital)

    Stress levels collected unobtrusively from smartwatch of patient to measure stress on a scale. This is a feature provided by the smartwatch. Patients will wear the smartwatch daily

    Measured: Continuous throughout 12 months

  26. Sleeping time

    Sleeping time (hours) collected unobtrusively from smartwatch of patient

    Measured: Continuous throughout 12 months

  27. Sleeping type

    Sleeping type (%) collected unobtrusively from smartwatch of patient

    Measured: Continuous throughout 12 months

  28. Hand and feet photos

    Images of hands and feet of the patient captured by the smartphone camera of the patient, to produce a feature vector relative to the condition of nails and joints of hands and toes resulting in an imaging digital biomarker

    Measured: 12 months (follow-up every 6 weeks and in case of flare)

  29. Hand and body movements videos

    Videos of pre-specified movements of hand and body recorded by the smartphone camera of the patient, to produce a set of time series with landmark coordinates (obtained from the videos) resulting in an imaging digital biomarker

    Measured: 12 months (follow-up every 6 weeks and in case of flare)

  30. Physical activity intensity and categories

    Physical activity intensity and physical activity categories collected unobtrusively from the smartwatch of patient to measure physical activity. Intensity and categories are features provided by the smartwatch. Patients will wear the smartwatch daily

    Measured: Continuous throughout 12 months

  31. Gyroscope sensor data

    Gyroscope sensor data for orientation collected unobtrusively from smartphone of patient

    Measured: Continuous throughout 12 months

  32. Keystroke Dynamics

    Keypad time-related data (e.g., inter-key press intervals) and associated metadata, collected unobtrusively from the patient's smartphone during app use, for fine motor function.

    Measured: Continuous throughout 12 months

  33. Session Frequency (iPROLEPSIS apps)

    Number of discrete user sessions or app log-ins over the study period, indicating engagement consistency and sustained participation.

    Measured: Continuous, through 12 months of follow-up

  34. Session Duration (iPROLEPSIS apps)

    Dwell time within each application, i.e., duration of each user session, in minutes.

    Measured: Continuous, throughout 11 months

  35. Feature Access Rate (iPROLEPSIS Apps)

    Number of times users access specific app features or modules, reflecting breadth and depth of feature engagement.

    Measured: Continuous throughout 12 months

  36. Task Completion Rate (iPROLEPSIS Apps)

    Ratio of the number of completed tasks to the number of abandoned or incomplete tasks

    Measured: Continuous throughout 12 months

  37. Notification Action Rate (iPROLEPSIS Apps)

    Ratio of the number of opened notifications to the number of resulting task completions

    Measured: Continuous throughout 12 months

  38. Time on Task (iPROLEPSIS Apps)

    Time taken by users to complete a defined in-app task, in minutes.

    Measured: Continuous throughout 12 months

  39. Error Rate (iPROLEPSIS Apps)

    Application) Ratio of the number of successful task attempts to the number of failed attempts (e.g., failed photo submissions or failed video tests).

    Measured: Continuous throughout 12 months

  40. User-Generated Data Entries (iPROLEPSIS Apps)

    Frequency and quantity of user-initiated data input, indicating active engagement and perceived app utility

    Measured: Continuous throughout 12 months

  41. Number of Dashboard Sessions Logged (HCP Dashboard)

    Number of times healthcare professionals log into the iPROLEPSIS clinical dashboard

    Measured: Continuous throughout 12 months

  42. Incremental Cost of Implementing the iPROLEPSIS Digital Health Programme Compared with Standard Care

    Estimated incremental cost (local currency) of implementing the iPROLEPSIS digital health tools vs. standard care, from a healthcare system perspective, including key cost drivers and sensitivity analyses.

    Measured: Baseline, T0 (Month 1), T3 (Month 4), and T11 (Month 12)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Aug 2026
  2. Study startSep 2026 (estimated)
  3. Primary completionDec 2027 (estimated)
  4. Study completionDec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
72 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07772544
Sponsor's protocol ID
014/2026/CENMS
Other IDs
101095697
Acronym
PPIDC
Status last verified
Sep 2026
First submitted
8 Aug 2026
Last updated
16 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in